Clinical Trial

Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
Trial Details
NCT Number NCT06942182
Lead Sponsor TNF Pharmaceuticals, Inc.
Conditions Sarcopenia in Elderly, Frailty, Frailty/Sarcopenia, Frailty in Older Adults
Enrollment 60 participants
Start Date 2025-05-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-04-24